Leukemia & Lymphoma

Test Your Knowledge

Quiz: What is the Most Common Type of Lymphoma?

11/17/2021

There are a number of different types of lymphomas. Which is the most common?

There are a number of different...

11/17/2021

Oncology

Debates and Roundtables

Advancements in the Management of Patients With T-Cell Lymphoma

01/05/2021

In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.

In the third part of this...

01/05/2021

Oncology

Debates and Roundtables

The Clinical Significance of the ECHELON-2 Trial

01/05/2021

In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.

In the second part of this...

01/05/2021

Oncology

Debates and Roundtables

Challenges in the Treatment of T-Cell Lymphoma

01/05/2021

In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.

In the first part of this...

01/05/2021

Oncology

Commentary

Chronic Myeloid Leukemia and Pregnancy

01/13/2020

Termination is not mandated for pregnant women receiving treatment for chronic myeloid leukemia.

Termination is not mandated for...

01/13/2020

Oncology

Videos

Should You Stop TKI Treatment for CML in Major Molecular Response?

12/23/2019

Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.

Sangmin Lee, MD, discusses...

12/23/2019

Oncology

News

Enasidenib Plus Azacitidine Improves Responses in Newly Diagnosed AML With IDH2 Mutations

12/19/2019

Enasidenib added to azacitadine is associated with significantly improved responses and significant mIDH2 VAF reductions compared with azacitadine monotherapy in patients with newly diagnosed AML With IDH2 mutations.

Enasidenib added to azacitadine...

12/19/2019

Oncology

Videos

Amer Zeidan, MBBS, MHS, Discusses Efficacy of Azacitdine Plus Durvalumab for AML, MDS

12/15/2019

Dr Zeidan discusses results from a study of azacitidine plus durvalumab in older patients with AML and high-risk MDS unfit for intensive chemo.

Dr Zeidan discusses results from...

12/15/2019

Oncology

News

Cerdulatinib Active in Patients With Relapsed/Refractory PTCL and CTCL

12/08/2019

Cerdulatinib demonstrated activity in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas, according to data being presented at ASH 2019.

Cerdulatinib demonstrated...

12/08/2019

Oncology